FDA APPROVES LESS POTENT FORMULA OF ALPHAGAN GLAUCOMA TREATMENT

Allergan announced that the FDA has approved a less potent version of its Alphagan drug to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension.

The new formulation of Alphagan contains 0.1 percent of the active ingredient, brimonidine tartrate ophthalmic solution, while the original Alphagan contains 0.2 percent.

Open-angle glaucoma is the most common form of glaucoma, and is characterized by pressure of the fluids inside the eye, optic nerve damage and visual field loss.